Adenosine was initially approved by the U.S. Food and Drug Administration (FDA) for medical use in the United States on October 30, 1989. It has been available as a prescription medication since then for the management of specific cardiac conditions, particularly supraventricular tachycardia (SVT). 

Adenosine is used to diagnose and treat supraventricular tachycardia (SVT) and as a stress agent in certain cardiac imaging tests.

Adenosine is administered intravenously (vein injection) under medical supervision. Your healthcare professional will determine the specific dosage and administration guidelines based on your condition and needs.

Common side effects of adenosine medication include flushing, chest discomfort or pain, shortness of breath, dizziness, lightheadedness, nausea, headache, and sweating. These side effects are usually transient and resolve quickly. Serious side effects, although rare, may include severe allergic reactions, chest pain, irregular heartbeat, fainting, and changes in blood pressure.

Adenosine can cause severe allergic reactions in some individuals. It can cause heart block, a condition where the electrical signals in the heart are delayed or blocked. This medication may cause bronchoconstriction, leading to breathing difficulties in individuals with asthma or COPD. Close monitoring is necessary in such cases. It can cause a transient drop in blood pressure, resulting in lightheadedness and dizziness. This medication may lower the seizure threshold, potentially increasing the risk of seizures in individuals with a history of seizure disorders. Elderly individuals may be more sensitive to the effects, particularly in terms of cardiovascular and respiratory responses. 

These precautions include considering the potential interactions of adenosine with other medications, especially methylxanthines, which may diminish its effects or lead to adverse reactions. Pregnancy and breastfeeding require careful consideration, as the safety of this medication in these situations has not been well established. Close monitoring is necessary during adenosine administration for individuals with pre-existing conditions such as asthma, COPD, heart block, or low blood pressure. Proper administration techniques and awareness of individual adenosine receptor sensitivity are also important. Discussing these precautions with a healthcare professional to ensure the safe and appropriate use of adenosine medication is essential.

Advice regarding Adenosine is to always consult with a healthcare professional before starting or making any changes to your medication regimen. They can assess your medical history, evaluate potential risks and benefits, provide personalized guidance, and monitor your progress throughout treatment. Additionally, closely follow the instructions and recommendations your healthcare provider gives, promptly report any unusual or concerning symptoms, and communicate openly about any concerns or questions you may have. It may interact with other medications, such as methylxanthines (e.g., caffeine, theophylline), which can diminish its effects or lead to adverse reactions. Precautions should be taken when using this medication in patients with liver or kidney impairment, as dosage adjustments or special monitoring may be required. The elderly population may be more sensitive to this medication's effects, and a specialist should determine pediatric use considering the child's specific condition. Pregnant and breastfeeding individuals should consult with healthcare professionals before using this medication. Your healthcare professional is the best resource for ensuring safe and effective medication use.

1. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Anti-arrhythmic drugs, 12th edition, 2011, 834.
2. KD Tripathi, Essentials of Medical Pharmacology, Antiarrhythmic drugs, 7th edition, 2013, 536.
3. Wockhardt UK Limited, Electronic medicines compendium (EMC), [ Revised on April 2019] [ Accessed on 10th July 2023], https://www.medicines.org.uk/emc/files/pil.4766.pdf
4. Astellas Pharma US, Inc, US Food and Drug Administration, [ Accessed on 10th July 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019937s026lbl.pdf

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.